US FDA risks eroding public trust with broad COVID-19 vaccines meeting – experts
The U.S. Food and Drug Administration's outside advisers will not be vetting any biopharmaceutical company's marketing application for a COVID-19 vaccine at the agency's Oct. 22 public meeting. Instead, the experts will discuss the general terms of development and emergency authorization or licensure of those products, the FDA said Aug. 27...
Hahn has some work to do to reestablish trust with the public and the FDA's independence after he misrepresented data about convalescent plasma Aug. 23 at the White House, said Rachel Sachs, associate professor of law at Washington University in St. Louis.